| scholarly article | Q13442814 |
| P50 | author | Werner J. Pichler | Q43088181 |
| P2093 | author name string | Klara K Eriksson | |
| Daniel Yerly | |||
| Stefano Fontana | |||
| Benno Schnyder | |||
| Jacqueline Adam | |||
| P2860 | cites work | HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol | Q24555784 |
| Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome | Q27335598 | ||
| Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity | Q27650811 | ||
| Optimization of the MHC class I peptide cargo is dependent on tapasin | Q28215565 | ||
| Medical genetics: a marker for Stevens-Johnson syndrome | Q28254047 | ||
| A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs | Q28264524 | ||
| The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes | Q28610405 | ||
| HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. | Q34005708 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Metabolic activation in drug allergies. | Q34133689 | ||
| Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept | Q34525501 | ||
| Activation of T cells by carbamazepine and carbamazepine metabolites | Q34543711 | ||
| Delayed drug hypersensitivity: models of T-cell stimulation | Q34976476 | ||
| Delayed Drug Hypersensitivity Reactions | Q35564139 | ||
| TAP genes and immunity | Q35876805 | ||
| The extent of the human germline T-cell receptor V beta gene segment repertoire | Q36752535 | ||
| Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction | Q36959209 | ||
| HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. | Q37385882 | ||
| Transfer and expression of three cloned human non-HLA-A,B,C class I major histocompatibility complex genes in mutant lymphoblastoid cells | Q37481068 | ||
| The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug | Q37535206 | ||
| Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen | Q39747188 | ||
| Design, expression, and processing of epitomized hepatitis C virus-encoded CTL epitopes | Q39926728 | ||
| Cross-reactivity patterns of T cells specific for iodinated contrast media | Q40148825 | ||
| Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells | Q40243201 | ||
| Stable human lymphoblastoid cell lines constitutively expressing hepatitis C virus proteins | Q40417596 | ||
| A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway | Q41106399 | ||
| Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome | Q42726783 | ||
| Processing-dependent and -independent pathways for recognition of iodinated contrast media by specific human T cells | Q43210075 | ||
| Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir | Q43527201 | ||
| Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity | Q44790837 | ||
| Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions | Q46930381 | ||
| Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. | Q53577380 | ||
| Activation of human dendritic cells by p-phenylenediamine. | Q53584690 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | abacavir | Q304330 |
| P304 | page(s) | 1706-1716 | |
| P577 | publication date | 2012-06-14 | |
| P1433 | published in | European Journal of Immunology | Q5412727 |
| P1476 | title | Avidity determines T-cell reactivity in abacavir hypersensitivity | |
| P478 | volume | 42 |
| Q35078628 | A novel rapid (20-minute) IL-6 release assay using blood mononuclear cells of patients with various clinical forms of drug induced skin injuries |
| Q54204422 | A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity. |
| Q28538078 | Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses |
| Q27008841 | Abacavir pharmacogenetics--from initial reports to standard of care |
| Q28543405 | Abacavir-reactive memory T cells are present in drug naïve individuals |
| Q54707780 | Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. |
| Q38286229 | Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions? |
| Q38534421 | Clinical Role of Human Leukocyte Antigen in Health and Disease. |
| Q92190152 | Dapsone- and nitroso dapsone-specific activation of T cells from hypersensitive patients expressing the risk allele HLA-B*13:01 |
| Q50624617 | Detection of Primary T Cell Responses to Drugs and Chemicals in HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity. |
| Q27012238 | Drug allergy: causes and desensitization |
| Q52346835 | Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. |
| Q48149225 | Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1/Th17 immune response. |
| Q26800980 | Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. |
| Q53353947 | Explanation for HLA-B*57:01-linked immune-mediated abacavir-induced hypersensitivity. |
| Q33582530 | Genotyping for severe drug hypersensitivity |
| Q38037649 | HLA and pharmacogenetics of drug hypersensitivity. |
| Q36343650 | HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects |
| Q61447461 | HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA observational database: a cohort study |
| Q47320133 | HLAs: Key regulators of T-cell-mediated drug hypersensitivity. |
| Q53361002 | Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. |
| Q26824391 | Idiosyncratic adverse drug reactions: current concepts |
| Q26995860 | Immediate-type hypersensitivity drug reactions |
| Q42392300 | Mechanisms involved in the Abacavir-mediated hypersensitivity syndrome |
| Q64241600 | Mechanisms of hypersensitivity reactions induced by drugs |
| Q41876196 | Novel Concepts for Drug Hypersensitivity Based on the Use of Long-Time Scale Molecular Dynamic Simulation |
| Q40969931 | Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions |
| Q51317293 | Peptide binding specificities of HLA-B*5701 and B*5801. |
| Q52702236 | Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions. |
| Q38689568 | Structural Elements Recognized by Abacavir-Induced T Cells |
| Q26747638 | T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance |
| Q92035357 | The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome |
| Q39427540 | The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions |
Search more.